3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Melanoma
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms, Castration-Resistant
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC Harboring NRG1 Fusion
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
pembrolizumab
5
tislelizumab
2
spartalizumab
2
Trastuzumab
2
Psychiatric Rehabilitation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-12 Subunit p35
2
Erlotinib Hydrochloride
2
Biopsy
2
trastuzumab deruxtecan
1
tipifarnib
1
regorafenib
1
prexasertib
1
niraparib
1
fludarabine
1
enzalutamide
1
entinostat
1
abiraterone
1
Vorinostat
1
Thalidomide
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Radionuclide Imaging
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
enzalutamide
×
Thoracic
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts